Literature DB >> 27283829

Proof-of-Concept of Polymeric Sol-Gels in Multi-Drug Delivery and Intraoperative Image-Guided Surgery for Peritoneal Ovarian Cancer.

Matthew McKenzie1, David Betts1, Amy Suh1, Kathryn Bui1, Rui Tang2, Kexian Liang2, Samuel Achilefu2, Glen S Kwon3,4, Hyunah Cho5.   

Abstract

PURPOSE: The purpose of this study is to investigate a sol-gel transition property and content release profiles for thermosensitive poly-(D,L-lactide-co-glycolide)-block-poly-(ethylene glycol)-block-poly-(D,L-lactide-co-glycolide) (PLGA-b-PEG-b-PLGA) hydrogels carrying paclitaxel, rapamycin, and LS301, and to present a proof-of-concept that PLGA-b-PEG-b-PLGA hydrogels carrying paclitaxel, rapamycin, and LS301, called TheranoGel, exhibit excellent theranostic activity in peritoneal ES-2-luc ovarian cancer xenograft mice.
METHODS: Thermosensitive PLGA-b-PEG-b-PLGA hydrogels carrying paclitaxel, rapamycin, and LS301, individually or in combination, were prepared via a lyophilization method, characterized with content release kinetics, and assessed with theranostic activity in ES-2-luc xenograft mice.
RESULTS: A thermosensitive PLGA-b-PEG-b-PLGA sol-gel system was able to entrain 3 poorly water-soluble payloads, paclitaxel, rapamycin, and LS301 (TheranoGel). TheranoGel made a sol-to-gel transition at 37°C and slowly released 3 drugs at a simultaneous release rate in response to the physical dissociation of hydrogels in vitro. TheranoGel enabled loco-regional delivery of multi-drugs by forming a gel-depot in the peritoneal cavity of ES-2-luc xenograft mice. An intraperitoneal (IP) administration of TheranoGel resulted in excellent therapeutic and diagnostic activities, leading to the improved peritoneal surgery in ES-2-luc xenograft mice.
CONCLUSIONS: TheranoGel prepared via a facile lyophiliation method enabled successful IP delivery of multi-drugs and exhibited excellent theranostic activity in vivo.

Entities:  

Keywords:  hydrogels; intraperitoneal; ovarian cancer; theranostics; thermosensitive

Mesh:

Substances:

Year:  2016        PMID: 27283829      PMCID: PMC7335463          DOI: 10.1007/s11095-016-1968-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

Review 1.  Prevention of postoperative peritoneal adhesions.

Authors:  Remah M Kamel
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2010-04-10       Impact factor: 2.435

2.  Hands-free, wireless goggles for near-infrared fluorescence and real-time image-guided surgery.

Authors:  Yang Liu; Adam Q Bauer; Walter J Akers; Gail Sudlow; Kexian Liang; Duanwen Shen; Mikhail Y Berezin; Joseph P Culver; Samuel Achilefu
Journal:  Surgery       Date:  2011-05       Impact factor: 3.982

Review 3.  Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.

Authors:  Maurie Markman; Joan L Walker
Journal:  J Clin Oncol       Date:  2006-02-06       Impact factor: 44.544

4.  Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels.

Authors:  Mingxi Qiao; Dawei Chen; Xichen Ma; Yanjun Liu
Journal:  Int J Pharm       Date:  2005-04-27       Impact factor: 5.875

Review 5.  Peritoneal adhesions: etiology, pathophysiology, and clinical significance. Recent advances in prevention and management.

Authors:  T Liakakos; N Thomakos; P M Fine; C Dervenis; R L Young
Journal:  Dig Surg       Date:  2001       Impact factor: 2.588

6.  Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.

Authors:  Hyunah Cho; Tsz Chung Lai; Glen S Kwon
Journal:  J Control Release       Date:  2012-12-13       Impact factor: 9.776

7.  Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.

Authors:  Monica M Mita; Alain C Mita; Quincy S Chu; Eric K Rowinsky; Gerald J Fetterly; Michelle Goldston; Amita Patnaik; Lesley Mathews; Alejandro D Ricart; Theresa Mays; Heather Knowles; Victor M Rivera; Jeff Kreisberg; Camille L Bedrosian; Anthony W Tolcher
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

8.  Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Authors:  Anne O'Donnell; Sandrine Faivre; Howard A Burris; Daniel Rea; Vassiliki Papadimitrakopoulou; Nicholas Shand; Heidi A Lane; Katharine Hazell; Ulrike Zoellner; John M Kovarik; Cathryn Brock; Suzanne Jones; Eric Raymond; Ian Judson
Journal:  J Clin Oncol       Date:  2008-03-10       Impact factor: 44.544

Review 9.  Hydrogel: Preparation, characterization, and applications: A review.

Authors:  Enas M Ahmed
Journal:  J Adv Res       Date:  2013-07-18       Impact factor: 10.479

10.  Treatment for recurrent ovarian cancer-at first relapse.

Authors:  Kimio Ushijima
Journal:  J Oncol       Date:  2009-12-24       Impact factor: 4.375

View more
  3 in total

1.  Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model.

Authors:  Dae Hwan Shin; Glen S Kwon
Journal:  J Control Release       Date:  2017-10-19       Impact factor: 9.776

Review 2.  Nanogels for Pharmaceutical and Biomedical Applications and Their Fabrication Using 3D Printing Technologies.

Authors:  Hyunah Cho; Udayabhanu Jammalamadaka; Karthik Tappa
Journal:  Materials (Basel)       Date:  2018-02-16       Impact factor: 3.623

Review 3.  Nanogels as a Versatile Drug Delivery System for Brain Cancer.

Authors:  Brielle Stawicki; Tyler Schacher; Hyunah Cho
Journal:  Gels       Date:  2021-05-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.